LONDON - Alizyme plc raised £11.5 million (US$19.5 million) in a placing of 6.8 million shares, giving it financial headroom as it negotiates deals for its three Phase III products, and allowing it to expand the commercial potential of its anti-obesity drug, ATL-962, by funding an additional Phase II trial in Type II diabetes. (BioWorld International)
LONDON - Alizyme plc raised £11.5 million (US$19.5 million) in a placing of 6.8 million shares, giving it financial headroom as it negotiates deals for its three Phase III products, and allowing it to expand the commercial potential of its anti-obesity drug, ATL-962, by funding an additional Phase II trial in Type II diabetes. (BioWorld International)
LONDON - The prospects of lifting the moratorium on genetically modified crops in Europe were undermined severely when the results of the biggest GM crop trials anywhere in the world concluded that herbicide-tolerant oil seed rape and sugar beet are more harmful to wildlife than conventional crops. (BioWorld International)
LONDON - The prospects of lifting the moratorium on genetically modified crops in Europe were undermined severely when the results of the biggest GM crop trials anywhere in the world concluded that herbicide-tolerant oil seed rape and sugar beet are more harmful to wildlife than conventional crops. (BioWorld International)
LONDON - Amersham plc, the UK's largest life sciences company, agreed to be taken over by General Electric Co. in a £5.7 billion (US$9.5 billion) deal that would create a $13 billion turnover business with a vision to drive the development of personalized medicine. (BioWorld International)
